---
layout: default
title: Irbesartan
description: "Irbesartan çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 4 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 93
evidence_level: L5
indication_count: 4
---

# Irbesartan

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>4</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Irbesartanï¼šå¾ é«˜è¡€å£“ åˆ° æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Irbesartan å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Irbesartanï¼ˆè‰¾æ¯”æ²™å¦ï¼‰æ˜¯ä¸€ç¨®è¡€ç®¡æ”¶ç¸®ç´  II å—é«”æ‹®æŠ—åŠ‘ï¼ˆARBï¼‰ï¼Œç”¨æ–¼æ²»ç™‚é«˜è¡€å£“å’Œç³–å°¿ç—…è…ç—…è®Šã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š (malignant hypertensive renal disease)** å’Œ**è‚ºé«˜å£“ (pulmonary hypertension)** æœ‰æ½›åœ¨é—œè¯ï¼Œç›®å‰ç„¡ç›´æ¥è‡¨åºŠè©¦é©—è­‰æ“šï¼Œä½†æ©Ÿè½‰ä¸Šå…·åˆç†æ€§ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç¬¬äºŒå‹ç³–å°¿ç—…æ‚£è€…çš„é«˜è¡€å£“åŠç³–å°¿ç—…æ€§è…ç—…è®Š |
| é æ¸¬æ–°é©æ‡‰ç—‡ | malignant hypertensive renal diseaseã€malignant renovascular hypertensionã€pulmonary hypertension with unclear multifactorial mechanismã€pulmonary hypertension owing to lung disease and/or hypoxia |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.31% (æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š) |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 30+ å¼µ |
| å»ºè­°æ±ºç­– | Consider |

## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Irbesartan é€éé¸æ“‡æ€§é˜»æ–·è¡€ç®¡æ”¶ç¸®ç´  II èˆ‡ AT1 å—é«”çš„çµåˆï¼Œç”¢ç”Ÿè¡€ç®¡æ“´å¼µå’Œé™å£“æ•ˆæœã€‚å…¶åŸé©æ‡‰ç—‡å·²åŒ…å«ã€Œç³–å°¿ç—…æ€§è…ç—…è®Šã€ï¼Œé¡¯ç¤ºå…¶å°è…è‡Ÿçš„ä¿è­·ä½œç”¨ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

**æ©Ÿè½‰æ”¯æŒï¼š**
- é˜»æ–· RAAS ç³»çµ±æ¸›å°‘è…çµ²çƒç¡¬åŒ–
- é™ä½è…å°çƒå…§å£“åŠ›
- æ¸›å°‘è›‹ç™½å°¿
- æŠ—çº–ç¶­åŒ–ä½œç”¨

å°æ–¼æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šï¼Œç©æ¥µæ§åˆ¶è¡€å£“æ˜¯æ²»ç™‚çš„æ ¸å¿ƒï¼ŒARB é¡è—¥ç‰©çš„è…è‡Ÿä¿è­·ä½œç”¨ä½¿å…¶æˆç‚ºåˆç†çš„æ²»ç™‚é¸æ“‡ã€‚ç„¶è€Œï¼Œã€Œæƒ¡æ€§ã€é«˜è¡€å£“é€šå¸¸éœ€è¦éœè„ˆæ³¨å°„è—¥ç‰©é€²è¡Œç·Šæ€¥è™•ç½®ï¼Œå£æœ ARB æ›´é©åˆä½œç‚ºç¶­æŒæ²»ç™‚ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å°æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šçš„ç›´æ¥è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

PubMed æ–‡ç»ä¸»è¦è¨è«–ä½æ°§èˆ‡å„ç¨®ç–¾ç—…çš„é—œä¿‚ï¼Œèˆ‡ irbesartan å°æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šçš„ç›´æ¥æ²»ç™‚æ•ˆæœç„¡é—œè¯æ€§ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.31%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary hypertension with unclear multifactorial mechanism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.25%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.25%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension owing to lung disease and/or hypoxia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.25%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.25%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026409è™Ÿ | è‰¾å¦¥æç©©è†œè¡£éŒ 300æ¯«å…‹ | è†œè¡£éŒ  | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç¬¬äºŒå‹ç³–å°¿ç—…æ‚£è€…çš„é«˜è¡€å£“åŠç³–å°¿ç—…æ€§è…ç—…è®Š |
| è¡›éƒ¨è—¥è£½å­—ç¬¬058169è™Ÿ | é™å£“ä½³è†œè¡£éŒ 150æ¯«å…‹ | è†œè¡£éŒ  | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç³–å°¿ç—…æ€§è…ç—…è®Š |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028450è™Ÿ | å„æ¯”å¡è†œè¡£éŒ 150æ¯«å…‹ | è†œè¡£éŒ  | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç³–å°¿ç—…æ€§è…ç—…è®Š |

## å®‰å…¨æ€§è€ƒé‡

**è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆä¸­åº¦ï¼‰ï¼š**
- Potassium supplementsï¼šå¯èƒ½å¢åŠ é«˜è¡€é‰€é¢¨éšª
- NSAIDsï¼šå¯èƒ½æ¸›å°‘é™å£“æ•ˆæœå’Œå¢åŠ è…æå‚·é¢¨éšª
- Lithiumï¼šå¯èƒ½å¢åŠ é‹°æ¯’æ€§
- ACE inhibitorsï¼šé›™é‡ RAAS é˜»æ–·å¢åŠ ä¸è‰¯åæ‡‰é¢¨éšª

**ç¦å¿Œç—‡ï¼š**
- æ‡·å­•
- é›™å´è…å‹•è„ˆç‹¹çª„
- åš´é‡è‚åŠŸèƒ½æå®³

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šMany psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially duri...
- å»ºè­°ï¼šCaution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihype...

**é«˜é‰€é£Ÿç‰© (Food High in Potassium)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šModerate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promo...
- å»ºè­°ï¼šPatients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substi...


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**å¿ƒè‡Ÿè¡°ç«­** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Hyperkalemia** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**Renal Artery Obstruction** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚

**ç³–å°¿ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Angioedema** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**ä½è¡€å£“** ğŸŸ¢ Minor
- å¯èƒ½éœ€è¦é™ä½åŠ‘é‡ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šConsider**

**ç†ç”±ï¼š**
Irbesartan çš„ ARB æ©Ÿè½‰å’Œå·²çŸ¥çš„è…è‡Ÿä¿è­·ä½œç”¨ï¼Œä½¿å…¶å°é«˜è¡€å£“æ€§è…ç—…è®Šçš„æ²»ç™‚å…·æœ‰è—¥ç†å­¸åˆç†æ€§ã€‚ç„¶è€Œï¼Œã€Œæƒ¡æ€§ã€é«˜è¡€å£“æ˜¯ä¸€ç¨®éœ€è¦ç·Šæ€¥è™•ç½®çš„æ€¥ç—‡ï¼Œå£æœ ARB æ›´é©åˆä½œç‚ºæ€¥æ€§æœŸå¾Œçš„ç¶­æŒæ²»ç™‚ã€‚é æ¸¬é©æ‡‰ç—‡å¯è¦–ç‚ºåŸé©æ‡‰ç—‡çš„åš´é‡ç¨‹åº¦å»¶ä¼¸ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å›é¡§æ€§ç ”ç©¶åˆ†æ ARB åœ¨æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šç¶­æŒæœŸçš„ç™‚æ•ˆ
- è©•ä¼°èˆ‡å…¶ä»–é™å£“è—¥çš„æ¯”è¼ƒæ•ˆç›Š
- æ˜ç¢ºæ­¤é©æ‡‰ç—‡æ˜¯å¦ç‚ºåŸé©æ‡‰ç—‡çš„è‡¨åºŠå»¶ä¼¸

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cephalexin]({{ "/drugs/cephalexin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Griseofulvin]({{ "/drugs/griseofulvin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pitavastatin]({{ "/drugs/pitavastatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alirocumab]({{ "/drugs/alirocumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ipilimumab]({{ "/drugs/ipilimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Irbesartanè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/irbesartan/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_irbesartan,
  title = {Irbesartanè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/irbesartan/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
